Camilla Cocchi

Camilla Cocchi

Auto-generated profile, based on publicly available information

Camilla Cocchi

Department of Ageing, Orthopedics and Rheumatology University “Cattolica del Sacro Cuore” Rome Italy

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Nutrition, Metabolism and Cardiovascular Diseases
Verified
Journal Article
Closed access
AMAnna Vittoria Mattioli
Anna Vittoria Mattioli
SSSusanna Sciomer
Susanna Sciomer
CCCamilla Cocchi
Camilla Cocchi
SMSilvia Maffei
Silvia Maffei
SGSabina Gallina
Sabina Gallina

19 March 2021 in Future Cardiology
Verified
Journal Article
Closed access
CCCamilla Cocchi
Camilla Cocchi
FCFrancesca Coppi
Francesca Coppi
CLCasoli Luciana
Casoli Luciana
AMAnna Vittoria Mattioli
Anna Vittoria Mattioli
Cardiovascular disease (CVD) is the leading cause of death among men and women, although women are usually underdiagnosed and experience a delay in diagnosis. This also occurs in women with type 2 ... Lay abstract Despite the fact that cardiovascular disease is the most frequent cause of death in women in industrialized countries, the idea that it affects mainly men and affects women only after ...

19 March 2025 in European Journal of Internal Medicine
Verified
Journal Article
Open access
CCCamilla Cocchi
Camilla Cocchi
MZMaria Beatrice Zazzara
Maria Beatrice Zazzara
ELElena Levati
Elena Levati
RCRiccardo Calvani
Riccardo Calvani
GOGraziano Onder
Graziano Onder
The global rise in aging populations is challenging healthcare systems, especially in developed countries. Despite advancements in healthcare and living standards, the extension of lifespan has not been matched by an equivalent improvement in healthspan, leading to a higher prevalence of chronic diseases and disabilities in older adults. This review examines strategies to promote healthy aging throughout the life cycle, emphasizing the importance of a comprehensive strategy that integrates individual, healthcare, and environmental approaches. Individual strategies include lifestyle factors like diet, physical activity, and social connections. Healthcare approaches focus on improving health literacy, vaccinations, and screenings. Environmental approaches aim to mitigate climate change, reduce pollution, and design longevity-ready cities. A comprehensive strategy combining individual approaches, public health measures, innovative policies, and community support is essential for helping populations live longer, healthier, and more independent lives. Looking forward, this will be complemented by personalized approaches, focusing on individual traits and biological backgrounds. The key to this lies in geroscience, which studies the biological and molecular mechanisms of aging and how they contribute to age-related diseases and functional decline, aiming to design targeted interventions to slow aging and improve quality of life. Artificial intelligence will play a key role in analyzing these complex factors and creating innovative solutions. In conclusion, aging is shaped by various factors, requiring more than one solution. A combination of comprehensive and personalized strategies can bridge the gap between public health measures and personalized care, offering the scientific insights needed to slow aging and enhance quality of life.

26 May 2021 in Diabetes Therapy
Verified
Journal Article
Open access
PDF file
GSGian Pio Sorice
Gian Pio Sorice
FCFrancesca Cinti
Francesca Cinti
Lucia LeccisottiLucia Leccisotti
Lucia Leccisotti
Domenico D'AmarioDomenico D'Amario
Domenico D'Amario
MLMargherita Lorusso
Margherita Lorusso
AGAndrea Giaccari
Andrea Giaccari
Introduction Sodium-glucose co-transporter-2 (SGLT-2) inhibitors have been shown to have beneficial effects on various cardiovascular (CV) outcomes in patients with type 2 diabetes (T2D) in primary prevention and in those with a high CV risk profile. However, the mechanism(s) responsible for these CV benefits remain elusive and unexplained. The aim of the DAPAHEART study will be to demonstrate that treatment with SGLT-2 inhibitors is associated with greater myocardial insulin sensitivity in patients with T2D, and to determine whether this improvement can be attributed to a decrease in whole-body (and tissue-specific) insulin resistance and to increased myocardial perfusion and/or glucose uptake. We will also determine whether there is an appreciable degree of improvement in myocardial-wall conditions subtended by affected and non-affected coronary vessels, and if this relates to changes in left ventricular function. Methods The DAPAHEART trial will be a phase III, single-center, randomized, two-arm, parallel-group, double-blind, placebo-controlled study. A cohort of 52 T2D patients with stable coronary artery disease (without any previous history of myocardial infarction, with or without previous percutaneous coronary intervention), with suboptimal glycemic control (glycated hemoglobin [HbA1c] 7–8.5%) on their current standard of care anti-hyperglycemic regimen, will be randomized in a 1:1 ratio to dapagliflozin or placebo. The primary outcome is to detect changes in myocardial glucose uptake from baseline to 4 weeks after treatment initiation. The main secondary outcome will be changes in myocardial blood flow, as measured by 13N-ammonia positron emission tomography/computed tomography (PET/CT). Other outcomes include cardiac function, glucose uptake in skeletal muscle, adipose tissue, liver, brain and kidney, as assessed by fluorodeoxyglucose (FDG) PET-CT imaging during hyperinsulinemic-euglycemic clamp; pericardial, subcutaneous and visceral fat, and browning as observed on CT images during FDG PET-CT studies; systemic insulin sensitivity, as assessed by hyperinsulinemic-euglycemic clamp, glycemic control, urinary glucose output; and microbiota modification. Discussion SGLT-2 inhibitors, in addition to their insulin-independent plasma glucose-lowering effect, are able to directly (substrate availability, fuel utilization, insulin sensitivity) as well as indirectly (cardiac after-load reduction, decreased risk factors for heart failure) affect myocardial functions. Our study will provide novel insights into how these drugs exert CV protection in a diabetic population. Trial registration EudraCT No. 2016-003614-27; ClinicalTrials.gov Identifier: NCT03313752.

1 October 2022 in European Heart Journal
Verified
Journal Article
Open access
PDF file
DDD D'AMario
D D'AMario
Lucia LeccisottiLucia Leccisotti
Lucia Leccisotti
FCFrancesca Cinti
Francesca Cinti
GSGian Pio Sorice
Gian Pio Sorice
MLMargherita Lorusso
Margherita Lorusso
FCF Crea
F Crea
Objective: Cardiovascular (CV) outcome trials have shown that in patients with type 2 diabetes (T2D), treatment with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduces CV mortality and admission rates for heart failure (HF). However, the mechanisms behind these benefits are not fully understood. This study was performed to investigate the effects of the SGLT-2i dapagliflozin on whole body insulin sensitivity, myocardial perfusion, and metabolism in patients with T2D without HF. Research design and methods: This was a single-center, prospective, randomized, double-blind controlled clinical trial including 16 patients with T2D randomized to SGLT-2i dapagliflozin (10 mg) or placebo. Whole body glucose uptake (WBGU) and myocardial glucose uptake (MGU) were measured with PET/CT with FDG during euglycemic hyperinsulinemic clamp. Stress (i.v. adenosine infusion) and resting myocardial blood flow (MBF) and myocardial flow reserve (MFR) were calculated by PET/CT with 13N-ammonia. Results: 16 patients were randomized (8 dapagliflozin; 8 placebo). The groups were well-matched for baseline characteristics (age, diabetes duration, HbA1c, renal and heart function). Dapagliflozin significantly improved MFR (2.56±0.26 vs 3.59±0.35) compared with placebo group (2.34±0.21 vs 2.38±0.24; p for interaction =0.001) and was associated to a reduction of resting MBF corrected for cardiac workload (p=0.045). A trend toward an increase in stress MBF was also detected (p=0.058). Moreover, in dapagliflozin group we observed an increase of WBGU of borderline statistical significance (p=0.06) and no effects on MGU (p=0.41). Conclusions: At the best of our knowledge, our study, for the first time, demonstrated that SGLT-2 inhibition increases MFR in T2D patients. The data presented provide a new potential explanation of cardiovascular benefits with SGLT-2i as they make patients more tolerant to the detrimental impact of obstructive coronary atherosclerosis on MFR. Funding Acknowledgement: Type of funding sources: None.

31 July 2026 in European Journal of Neurology
Verified
Journal Article
Open access
CCCamilla Cocchi
Camilla Cocchi
GRGiulia Renda
Giulia Renda
SGSabina Gallina
Sabina Gallina
AMAnna Vittoria Mattioli
Anna Vittoria Mattioli